Paul A. Bunn, MD

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Paul A. Bunn, MD, distinguished professor, Division of Medical Oncology, and James Dudley Chair in Lung Cancer Research, University of Colorado, discusses the initial results of the ongoing MYSTIC trial, which is exploring the combination of durvalumab (Imfinzi) and tremelimumab versus chemotherapy in stage IV lung cancer.